öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÁõ½¨Æ½
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º186

ËùÊôԺУ£ºÖйúÒ©¿Æ´óѧ
ËùÊôԺϵ£ºÒ©Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©¼Áѧ¡¢Ò©Ñ§£¨¹¤ÒµÒ©Ñ§·½Ïò£©
Ñо¿ÁìÓò£º ÉúÎ﹦ÄÜÐÔÒ©ÎïÔØÌ壬»º¿ØÊÍÖƼÁ¡¢¾­Æ¤¸øҩϵͳ¡¢ÖÐҩмÁÐÍ
Ñо¿ÁìÓò£º ÉúÎ﹦ÄÜÐÔÒ©ÎïÔØÌ壬»º¿ØÊÍÖƼÁ¡¢¾­Æ¤¸øҩϵͳ¡¢ÖÐҩмÁÐÍ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºjianpingliu1293@163.com


¸öÈ˼òÊö :
1982Äê±ÏÒµÓÚÖйúÒ©¿Æ´óѧҩѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬ÏÖΪÖйúÒ©¿Æ´óѧҩ¼ÁÑо¿ËùËù³¤¡¢Ò©¼Á½ÌÑÐÊÒ¸±Ö÷ÈΣ¬Ò©¼Áѧ²©Ê¿¡¢½ÌÊÚ¡¢²©Ê¿Éúµ¼Ê¦¡£1999Ä기ÐÂÎ÷À¼Otago´óѧҩѧԺ½øÐÞ¡£¼æÈιú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö±£½¡Æ·ÉóÆÀר¼Ò¡¢Å©Òµ²¿ÊÞÒ©ÉóÆÀר¼Ò¡¢½­ËÕÊ¡Ò©¼ÁöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈΡ¢½­ËÕÊ¡Ò©Æ·±£½¡Æ·ÖƼÁÉóÆÀר¼Ò¡¢½­ËÕÊ¡¾ÅÈýѧÉçҽҩίԱ»áίԱµÈÖ°¡£

¿ÆÑй¤×÷ :
Ö÷ÒªÑо¿ÄÚÈݺͳɹû£ºÀûÓÃѪ½¬¸ßÃܶÈÖ¬µ°°×ÄæתÔ˵¨¹Ì´¼£¬¾ßÓп¹¶¯ÂöÖàÑùÓ²»¯µÄÐÔÖʺÍ×÷Óã¬ÖØ×é¸ßÃܶÈÖ¬µ°°×ÔØҩϵͳ£¬´ïµ½ÔØÌåÓëÒ©ÎïµÄЭͬÖÎÁÆ×÷Ó㬻ñ2Ïî¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿×ÊÖú£»Õë¶ÔÖÐÒ©¶à³É·ÖÌåÄÚ¹ý³Ì²îÒì½Ï´ó£¬²»ÀûÓÚ·¢»ÓЭͬ×÷ÓõÄÎÊÌ⣬¶ÔÖÐÒ©¶à³É·ÖÌåÄÚ¹ý³Ì½øÐÐÒ©¶¯Ñ§ÓëҩЧѧµÄ¶þ´Îµ÷¿ØÓë¸ÄÔ죬»ñ1Ïî¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿×ÊÖú¡£Ö÷³Ö¿Æ¼¼²¿¡°Ê®Ò»Î塱ÖØ´óרÏî¡¢¹ú¼ÒÖÐÒ½Ò©¹ÜÀí¾ÖÏîÄ¿¡¢½­ËÕÊ¡¡°Áù´óÈ˲š±¸ß·åÏîÄ¿¡¢½­ËÕÊ¡×ÔÈ»¿Æѧ»ù½ð¡¢½­ËÕÊ¡Éç»á·¢Õ¹»ù½ðµÈÏîÄ¿ÏîÄ¿£¬¸ºÔð»ò²ÎÓë¿Æ¼¼²¿¡°Ê®Î塱¹ú¼Ò¿Æ¼¼¹¥¹Ø¡¢¡°Ê®Ò»Î塱¹ú¼Ò¿Æ¼¼Ö§³Å¼Æ»®¡¢ÐÂÎ÷À¼¹ú¼ÊºÏ×÷ÏîÄ¿¡¢½­ËÕÊ¡¸ßм¼ÊõÕбêÏîÄ¿¡¢½­ËÕÊ¡¿Æ¼¼»ù´¡ÉèÊ©½¨Éè¼Æ»®-¿Æ¼¼¹«¹²·þÎñƽ̨ÏîÄ¿¡¢½­ËÕÊ¡ÖÐÒ½Ò©¹ÜÀí¾ÖÏîÄ¿ÒÔ¼°ÆóÒµºÏ×÷¿ª·¢ÏîÄ¿µÈ¹²25Ïͨ¹ý½­ËÕÊ¡¿Æ¼¼Ìü³É¹û¼ø¶¨ÈýÏ»ñ2004ÄêÄϾ©ÊпƼ¼½ø²½½±ÈýµÈ½±¡¢2011¹ú¼ÒÈ˿ںͼÆÉúίÓÅÐã¿Æ¼¼³É¹ûÒ»µÈ½±£¬ÉêÇë·¢Ã÷רÀû27ÏÒÑÊÚȨ9Ïî¡£·¢±íÂÛÎÄ129ƪ£¨ÆäÖÐSCI 42ƪ¡¢EIÊÕÔØ2ƪ£©¡£
½ü3Äê·¢±íµÄ´ú±íÐÔÂÛÎÄ£¨ÒÔϾùΪͨѶ×÷Õߣ©
1. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation [J]. Journal of Controlled Release, 2015, 23(10): 161-169.(SCI£¬7.705)2. Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein[J]. Pharmaceutical Research, Published online£º04 June 2015.(SCI£¬3.952)3. Tanshinone IIA loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation[J]. European Journal of Pharmaceutical Sciences, 2015, 76(2015): 156¨C164.(SCI£¬3.35)4. Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug [J]. Pharmaceutical research, 2015, 32(4): 1451-1461. (SCI£¬3.952)5. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473 (1¨C2), 528¨C535. (SCI£¬3.785)6. Hyaluronic acid-decorated reconstitude high density lipoprotein targeting atherosclerotic lesion [J]. Biomaterials, 2014, 35(27): 8002¨C8014. (SCI£¬8.312)7. Arachidonic Acid-modified Lovastatin Discoidal Reconstituted High Density Lipoprotein Markedly Decrease the Drug Leakage during the Remodeling Behaviors Induced by Lecithin Cholesterol Acyltransferase. Pharmaceutical Research, 2014, 31(7): 1689-1709. ( SCI£¬ 3.952)8. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins, Biomaterials, 2013, 34(1):306-319. (SCI£¬ 7.604)9. Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug¨Cphospholipids complex technique. European journal of pharmaceutics and biopharmaceutics, 2013,83(1):76-86. (SCI£¬3.826)10. Release Behavior of Tanshinone IIA Sustained-Release Pellets Based on Crack Formation Theory. Journal of pharmaceutical sciences, 2012,101(8):2811-2820. (SCI£¬3.055)11. Preparation, Characterizations, and In Vitro Metabolic Processes of Paclitaxel-Loaded Discoidal Recombinant High-Density Lipoproteins. Journal of pharmaceutical science, 2012,101(8):2900-2908. (SCI£¬3.055)12. Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2012,80:426-432. (SCI£¬4.269)